作者: Krishna Bajee SRIRAM , Jill Everland LARSEN , Ian Anthony YANG , Rayleen Veronica BOWMAN , Kwun Meng FONG
DOI: 10.1111/J.1440-1843.2010.01892.X
关键词:
摘要: Lung cancer is the commonest cause of cancer-related mortality and non-small cell lung (NSCLC) accounts for 80% all cancer. The prognosis NSCLC remains poor across stages, despite advances in staging techniques treatments. findings recent high-throughput mRNA microarray studies have shown potential refining current diagnosis, classification, treatment paradigms. Emerging microRNA, DNA copy number methylation profiles are also providing novel insights into biology NSCLC. Currently there several challenges, such as reproducibility cost platforms that will need to be addressed prior implementation these genomic technologies routine thoracic oncology practice. In addition, tests (such prediction gene expression signatures) validated well designed prospective aim answer clinically relevant questions. If successful, integration microarray-based information with existing clinicopathological models may enhance ability clinicians match most effective an individual patient. Such a strategy improve survival reduce treatment-related morbidity patients.